Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Portfolio Pulse from
Eli Lilly's shares fell by 6% after the company reduced its 2024 revenue guidance due to lower-than-expected demand for its obesity and diabetes drugs.
January 14, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's stock price fell by 6% following a reduction in its 2024 revenue guidance. The company cited lower-than-expected demand for its obesity and diabetes drugs as the reason for the guidance cut.
The reduction in revenue guidance directly impacts investor expectations and sentiment, leading to a 6% drop in Eli Lilly's stock price. The lower demand for key drugs suggests potential challenges in meeting future revenue targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100